CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N. Shah, Terry J. Fry, Constance M. Yuan et al.|Journal of Clinical Oncology|2020Cited by 422
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell LeukemiaDai Chihara, Robert J. Kreitman, Evgeny Arons et al.|Journal of Clinical Oncology|2020Cited by 104
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering MyelomaDickran Kazandjian, Ola Landgren, Elizabeth Hill et al.|JAMA Oncology|2021Cited by 46
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicityJennifer Jess, Nirali N. Shah, Bonnie Yates et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 35
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variantDai Chihara, Robert J. Kreitman, Evgeny Arons et al.|Blood Advances|2021Cited by 28